A group of researchers led by Osaka University established a new pathological grading system to evaluate the therapeutic effect of neoadjuvant chemotherapy (NAC) for metastatic lymph nodes (LNs) removed in oesophageal cancer (EC) surgery, demonstrating that the system predicts recurrence and prognosis in EC patients better than conventional systems.
Their research results were published in Annals of Surgery.
The majority of patients with progressive EC have LN metastases.
Such patients usually receive NAC before surgery.
Since patients who showed good response to NAC are known to have a favourable prognosis, it is important to accurately evaluate the therapeutic effect of NAC.
Routine pathological evaluation of NAC is conducted for the therapeutic effect on the primary tumour (PT).
PT regression grade is determined by calculating the proportion of viable tumour area within the whole tumour bed area.
Evaluations are classified into four categories according to the proportion.
A high grade shows a high therapeutic effect of NAC.
This tumour regression grade classification is a good indicator for predicting recurrence and prognosis.
Because metastatic status of LN, which is known to be associated with systemic micrometastases, serves as a more reliable indicator of patient survival compared with PT progression in EC patients, this group hypothesised that, in patients who have undergone NAC for EC, the pathological LN response might be a better prognostic factor than the pathological PT response.
Among 371 eligible patients, 52 had negative LNs with no evidence of regression.
The researchers evaluated the therapeutic effect of NAC for the remaining 319 patients by grading pathological tumour regression into four categories according to residual tumour per tumour bed.
For all metastatic LNs, the researchers generated a total LN regression grade according to the proportion of the summed viable tumour area relative to the summed tumour bed area (Figure 1I).
153 patients (48.0%) exhibited better response and 191 (59.9%) showed a difference in response between the PT and LN regression grades. Specifically:
These findings show that pathological assessment of all metastatic LNs is excellent in predicting prognosis and disease recurrence in patients who undergo NAC for EC.
Lead author Professor Tomoki Makino says, "We've found that it is possible to predict disease recurrence and prognosis by performing pathological assessment of all metastatic LNs. Moving forward, this will enable 'tailor-made' treatment according to the pathological assessment of all metastatic LNs, eventually improving treatment performance of EC."
Source: Osaka University
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.